Key result
Systemic breast cancer therapies, particularly anthracyclines and trastuzumab, can cause significant cardiovascular toxicities, highlighting the need for early detection, monitoring, and management strategies.
Systemic breast cancer therapies can cause significant cardiovascular toxicity, highlighting the need for understanding mechanisms, utilizing biomarkers, and implementing preventive strategies.
Answers are grounded in this paper and cite their sources.
Supports cardio-oncology vigilance during breast cancer therapy; leaves open prospective validation of biomarker-guided strategies.
Cardiovascular toxicity is unfortunately a potential short- or long-term sequela of breast cancer therapy. Both conventional chemotherapeutic agents such as anthracyclines and newer targeted agents such as trastuzumab can cause varying degrees of cardiac dysfunction. Type I cardiac toxicity is dose-dependent and irreversible, whereas Type II is not dose-dependent and is generally reversible with cessation of the drug. In this review, we discuss what is currently known about the cardiovascular effects of systemic breast cancer treatments, with a focus on the putative mechanisms of toxicity, the role of biomarkers, and potential methods of preventing and minimizing cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2014) conducted a review in Breast cancer. Systemic breast cancer therapy (anthracyclines, trastuzumab, and other targeted agents) was evaluated. Systemic breast cancer therapies, particularly anthracyclines and trastuzumab, can cause significant cardiovascular toxicities, highlighting the need for early detection, monitoring, and management strategies.
Synapse has enriched 10 related papers. Consider them for comparative context: